CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
Vandana Midha, Ramit Mahajan, Varun Mehta, Vikram Narang, Arshdeep Singh, Kirandeep Kaur, Ajit Sood
Intest Res. 2018;16(1):83-89.   Published online January 18, 2018
DOI: https://doi.org/10.5217/ir.2018.16.1.83

Excel Download

Efficacy and safety of the adalimumab biosimilar Exemptia as induction therapy in moderate-to-severe ulcerative colitis
Intestinal Research. 2018;16(1):83   Crossref logo
Link1 Link2 Link3

<p>Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up</p>
Biologics: Targets and Therapy. 2019;Volume 13:191-200   Crossref logo
Link1 Link2

Su1213 Efficacy and Safety of Biosimilar of Infliximab in Rescue Therapy in Adult Patients With Severe Ulcerative Colitis
Gastroenterology. 2016;150(4):S497   Crossref logo
Link1 Link2

Comparative efficacy and safety of golimumab, infliximab and adalimumab for the treatment of moderate to severe ulcerative colitis: A bayesian indirect treatment comparison meta-analysis
Value in Health. 2014;17(3):A35   Crossref logo
Link1 Link2

Biologic Therapy in Moderate-to-Severe Ulcerative Colitis: Infliximab
Crohn's Disease and Ulcerative Colitis. 2017;429-433   Crossref logo
Link1

Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
Therapeutics and Clinical Risk Management. 2013;451   Crossref logo
Link1

Response to Jani et al . A prospective, randomized, doubleblind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
International Journal of Rheumatic Diseases. 2015;20(11):1791-1791   Crossref logo
Link1 Link2 Link3

A randomized double-blind trial comparing the efficacy, safety, and immunogenicity of MSB11022, a proposed biosimilar of adalimumab, versus adalimumab originator in patients with moderate-to-severe plaque psoriasis
Journal of the American Academy of Dermatology. 2018;79(3):AB21   Crossref logo
Link1 Link2

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
Gastroenterology. 2012;143(1):e42   Crossref logo
Link1 Link2

Biologic Therapy of Ulcerative Colitis: Adalimumab
Crohn's Disease and Ulcerative Colitis. 2017;435-439   Crossref logo
Link1